Lm reversed gut dysbiosis and restored the abundance of commensal bacteria genera ( Faecalibaculum , Coriobacteriaceae UCG 002, Lactococcus , Negativibacillus , Turicibacter , Ruminiclostridium 6, Parasutterella , Eubacterium xylanophilum group, Ruminococcaceae UCG 010, and Staphylococcus ) which are mainly SCFAs producers resulting in enhanced intestinal barrier integrity
We assist by offering natural food supplements in combination with professional guidance
These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Companys products and services, the Companys ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Companys filings with the U.S
There is one Phase I trial registered as NCT02637284 in 2015, intended to enrol forty-two participants, which was subsequently cancelled with no published results [7]